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Transparency, openness, and reproducibility are important characteristics in scientific publishing.
Although many researchers embrace these characteristics, data sharing has yet to become common
practice. Nevertheless, data sharing is becoming an increasingly important topic among societies,
publishers, researchers, patient advocates, and funders, especially as it pertains to data from clinical
trials. In response, ASTRO developed a data policy and guide to best practices for authors sub-
mitting to its journals. ASTRO's data sharing policy is that authors should indicate, in data
availability statements, if the data are being shared and if so, how the data may be accessed.
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Researchers are increasingly expected to make their
data findable, accessible, interoperable, and reusable
(FAIR),1 with the goal of generating new scientific in-
sights that ultimately benefit patients. This is especially
true for publicly (eg, National Institutes of Health
[NIH]) funded research and was further evidenced by
the Open Government Data Act that went into effect on
July 15, 2019.2 Given the symbiotic relationship that
exists between science and society, scientific journals
can play an important role in cultivating a culture of data
sharing. Journals bear much responsibility for facili-
tating scientific discovery and maintaining credibility
with the public by publishing studies that embrace
transparency and invite reproducibility. Although dia-
logue surrounding data sharing should also occur further
upstream (eg, during funding and research proposal
stages), journal editorial teams and publishers can play a
key role in educating authors about the benefits of data
sharing and related best practices. Policies and ap-
proaches to data sharing may slightly vary by funder or
publisher, nevertheless ASTRO strives to minimize
ambiguity around data sharing and highlight approaches
that maximize transparency, discovery, and scientific
reuse of data.
ASTRO Journals’ Data Sharing Policy
ASTRO does not require data sharing. In the interest of
transparency and in support of FAIR data principles,
however, authors are asked to include a data availability
statement with their submitted work. Data availability
statements should indicate whether the data are being
shared and if so, how the data may be accessed. Data
availability statements will be published alongside articles
submitted after this policy goes into effect (on January 1,
2020).
Data Availability Statements
Data availability statements are short descriptions
included with scientific publications that provide readers
with the conditions surrounding access to data underlying
the research being reported. The overarching goals of
publishing data availability statements are to facilitate
quick identification of relevant data in a study, to promote
transparency in all instances of access or restriction, and
to increase awareness of data availability statement
structure.
A data availability statement should include (1) a
description about the data underlying the article (eg, the
type of data analyzed in the study); (2) a declaration of
whether the data are available for reuse, and howreaders may access the data (including but not limited to
licensing or proposal review); (3) the name of the re-
pository or platform hosting the data and a persistent
identifier link to the data object(s)dtypically a digital
object identifier (DOI); and (4) if applicable, a statement
on data sharing restrictions or unavailability (eg,
embargoed data).
Data included in data availability statements should be
cited within the text and listed in the references section.
Examples of data availability statements are shown in
Table 1.Research Data Sharing Best Practices
ASTRO encourages authors to share research data at
the minimum that is necessary to understand, evaluate,
replicate, and build upon reported findings by the time of
publication, following health information privacy stan-
dards,3 and scholarly publishing community best practices
around data deposition and citation.4 The definition of
research data here is derived from the United States Office
of Management and Budget,5 which states:
Research data means the recorded factual material commonly
accepted in the scientific community as necessary to validate
research findings, but not any of the following: preliminary
analyses, drafts of scientific papers, plans for future research,
peer reviews, or communications with colleagues. This
“recorded” material excludes physical objects (eg, laboratory
samples). Research data also do not include (i) Trade secrets,
commercial information, materials necessary to be held
confidential by a researcher until they are published, or
similar information which is protected under law; and (ii)
Personnel and medical information and similar information
the disclosure of which would constitute a clearly unwar-
ranted invasion of personal privacy, such as information that
could be used to identify a particular person in a research
study.
In practice, data sharing may not only be considered at
subject level data but may consist of derived data and data
products such as software or code used to generate, pro-
cess, or interpret data that are reported in an article (eg,
figures and analyses). Ideally, data sets will be deposited
in discipline-specific, community-recognized repositories,
cited in text and listed in the reference section after the
Joint Declaration of Data Citation Principles.6 Previously
published methods and data should likewise be cited. An
example data set citation is:
Le Noury JC, Nardo JM, Healy D, Jureidini J, RavenM,
Tufanaru C, Abi-Jaoude E. (2015) Data from: Restoring
Study 329: Efficacy and harms of paroxetine and imipra-
mine in treatment of major depression in adolescence.
DryadDigital Repository. Available at: https://doi.org/10.5
061/dryad.bv8j6. Accessed May 29, 2019.
Data must be uniquely identifiable and persistent to be
findable and accessible by machines and humans. DOIs,
Table 1 Data availability statement examples
Category Example statement(s) Published in
All data available 1. Clinical study reports, detailed data tables, and pro-
gramming code are available on the Dryad Digital Re-
pository (https://doi.org/10.5061/dryad.bv8j6) and at
www.Study329.org/.
British Medical Journal
2. Patient level data for this study is available at: http://
www.gsk-clinicalstudyregister.com/study/29060/329.
GlaxoSmithKline Study Register
3. All data generated and analyzed during this study are
included in this published article (and its supplementary
information files).
Third-party data 1. This study was based on the English national cancer
registry data. The authors do not own these data and
hence are not permitted to share them in the original form
(only in aggregate form, eg, publications). At the time of
request data were provided by the Office for National
Statistics but now all cancer registrations are owned and
maintained by Public Health England.
British Medical Journal
2. Data are available from the UK Biobank for researchers
who meet the criteria and gain approvals to access the
research database from the UK Biobank access man-
agement committee at the University of Oxford. Appli-
cations are reviewed and approvals granted subject to
meeting all ethical and research conditions set forth by
the UK Bio Bank. Information on access procedures,
general enquiries, and contact information can be found
online: https://www.ukbiobank.ac.uk/key-uk-biobank-
contacts/. The full code for the analysis is available at:
https://github.com/PRISM-UoN/UK-Bio-Bank-Machine-
Learning-Project.
PLOS One
Restricted access (commercial) Data for these analyses were made available to the authors
through third-party license from Optum and Truven, 2
commercial data providers in the United States. As such,
the authors cannot make these data publicly available due
to data use agreement. Other researchers can access these
data by purchasing a license through Optum and Truven.
Inclusion criteria specified in the Methods section would
allow other researchers to identify the same cohort of
patients we used for these analyses. Interested individuals
may see https://www.optum.com/solutions/prod-nav/
product-data.html for more information on accessing
Optum data and https://marketscan.truvenhealth.com/
marketscanportal/for more information on accessing
Truven data.
PLOS Med
Restricted access (legal/ethical) It is Novartis Policy not to share data from interim trial
results, even if a Health Authority approval has been
granted based only on interim trial data. Novartis will
share data when the trial CSR is completed, and the
results published.
Clinical Study Data Request
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articles, are unique and persistent, and are able to be
assigned to data (as shown in the example reference
above). It is prudent to deposit data into a repository that
issues a DOI. Studies that provide underlying data via a
persistent identifier have been shown to have a 25%
citation advantage over studies that do not point tounderlying data at all.7 The growth of data citation
practices are further evidenced by Clarivate Analytics’
launch of Data Citations Index.8 DOIs are essential for
providing the linkages that allow data and other digital
outputs to be discovered and referenced.
One misconception about FAIR data is that all data
should be open. This is not the case; one should describe
554 D. Tegbaru et al Advances in Radiation Oncology: OctobereDecember 2019how data can be accessed. If data sharing restrictions
exist, the data availability statement should describe to
readers what the limitations are and how qualified per-
sons, if applicable, may be approved to access data for
research purposes. As an example, commercially spon-
sored research terms that require an embargo to ensure
proper management of trade secrets may restrict access to
data.
Furthermore, ASTRO Journals share the International
Committee of Medical Journal Editors belief that there is
an ethical obligation to responsibly share data generated
by interventional clinical trials. As such, ASTRO sup-
ports the International Committee of Medical Journal
Editors' requirement that a data sharing plan be included
in the trial's registration and that the article reporting
clinical trial results should include a data sharing state-
ment indicating whether deidentified participant data
(including data dictionaries) will be shared; whether
additional, related documents will be available (eg,
study protocol, statistical analysis plan, etc.); when the
data will become available and for how long; and by
what access criteria data will be shared (including
with whom, for what types of analyses and by what
mechanisms).9
Data repositories
Authors should select repositories most appropriate for
their research; in particular, domain repositories that host
data from their discipline or subdiscipline should be
considered (see also NIH-supported data repositories10
and Data Cite's FAIR data repository finder).11 If such a
repository is not available, general repositories that assign
DOIs or institutional repositories can be used. A list of
potential repositories is also provided in Table 2 as a
general resource. Additional educational resources on
data, metadata standards, journals and funder data sharing
policies are available at https://fairsharing.org/.
Data sharing restrictions
Sharing research data may be restricted due to in-
tellectual property or privacy concerns determined by
national laws, research sponsor policies, and copyright
licensing agreements. More commonly, restrictions
may be attributed to data disclosure risks or third-party
data.
 Data disclosure risks: Institutional or commercially
sponsored research will typically include trained
data curators who apply anonymization standards to
protect confidentiality. If there are possible data
disclosure risks, that is, where privacy or legal
concerns exist, authors should specify in their data
availability statement if restricted-use data areavailable (eg, through a data use agreement) and
identify the group to which requests should be
submitted. The reasons for restrictions provided
through the data availability statement should be
unambiguous. It is not best practice for the authors
to be the sole named individuals responsible for
ensuring data access.
 Third party data: Third-party data refers to data that
cannot be legally distributed by the authors. Au-
thors should share any data specific to their anal-
ysis that they can legally distribute. If authors do
not have the rights to distribute the data, they
should include all necessary contact information in
the data availability statement to gain access to the
relevant data. If permission is required to use a
third-party data set, authors should include the
third-party source and verification of permission in
the data availability statement, as well as provide
proper acknowledgment in the article. (Adapted
from Earth Science Information Partners CC
BY.)26
When access to data is restricted, authors should
disclose terms of use or unavailability in their article’s
data availability statement. Note that several data re-
positories listed in Table 2 support restricted access.Data anonymization and intellectual property
Barriers to productive reuse of sensitive data can be
reduced through standardized data anonymization; careful
review of sponsored research agreements; and clear
marking of reuse permissions by rightsholders.
Direct and indirect identifiers that risk research sub-
ject's confidentiality should be masked and randomized to
ensure compliance with privacy laws and guidelines, thus
allowing data to be shared for research purposes. Section
164.514(a) of the Health Insurance Portability and
Accountability Act of 1996 Privacy Rule provides a
standard for deidentification of protected health informa-
tion using either the Expert Determination or Safe Harbor
methods.27 The European General Data Protection
Regulation also provides guidance on deidentification.28
Novartis, a global pharmaceutical company, provides a
comprehensive example on how to generate compliant
deidentified data sets.29
Researchers considering sharing or reusing data may
raise questions about intellectual property. Data sharing
restrictions are commonly attributed to commercial trade
secrets (or proprietary information), patents, and copy-
right. Proprietary data from industrial or commercially
sponsored research may have implications for future
patents; as a result, a researcher collaborating with a
pharmaceutical company may be contractually bound to
embargo their research data for a set period.30 Sponsored
Table 2 Potential data repositories*
Description DOI provided?
Clinical Study Data Request (CSDR) A consortium of clinical study sponsors or funders. CSDR
facilitates restricted access to patient-level data from clinical
studies.12
N/A
Dryad General repository. Dryad collects a data publishing charge of
$120 upon data publication, unless there is a sponsor or fee
waiver in place. Additional charges apply to data packages in
excess of 20 GB. See also frequently asked questions.13
Yes
Figshare Free to use general repository, which allows up to 5 GB per file
upload.14 Supports restricted access and can accommodate
double-blind review.15
Yes
Mendeley Data A free to use general repository (up to 10 GB per data set). See also
frequently asked questions.16
Yes
OpenScience Framework Free to use general repository, which allows up to 5 GB per file
upload.17
Yes
Project Data Sphere Nonprofit, online platform that facilitates sharing and analysis of
historical, patient-level data from academic and industry phase
III cancer clinical trials. Deidentification of patient level data are
the responsibility of the data provider.18
No
Synapse Open source biomedical research platform for data sharing,
analysis, and collaboration. Supports restricted access.19
Yes
The Cancer Imaging Archive (TCIA) TCIA hosts an archive of cancer imaging for public consumption.
Their Clinical Trials Processor software performs
deidentification and curation according to Digital Imaging and
Communications in Medicine (DICOM) standards.20,21
Yes
Genomic Data Commons (GDC) The GDC contains National Cancer Institute (NCI)-generated data
from some of the largest and most comprehensive cancer
genomic data sets, including The Cancer Genome Atlas and
Therapeutically Applicable Research to Generate Effective
Therapies.22
No
Sequence Read Archive (SRA) The SRA is NIH's primary archive of high-throughput sequencing
data and is part of the International Nucleotide Sequence
Database Collaboration that includes at the NCBI SRA, the
European Bioinformatics Institute, and the DNA Database of
Japan. Data submitted to any of the 3 organizations are shared
among them.23
No
Vivli Nonprofit, data sharing and analytics platform created to sharing of
individual participant-level data from completed clinical trials.
Vivli partners with Privacy Analytics, who assists with
anonymization.24
Yes
Zenodo General repository. Zenodo accepts up to 50 GB per data set.
Monetary donations are encouraged to maintain the repository.25
Can accommodate double-blind review.15
Yes
* ASTRO does not endorse any specific repositories and is not responsible for any data deposited. The list of potential repositories is provided as a
general resource from and for the scientific community. If your repository of choice is not listed and would like to submit a recommendation for
ASTRO's data sharing frequently asked questions page, please e-mail journals@astro.org.
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lectual property policies would establish guidelines
for ownership and disclosure of proprietary
information.31,32
Copyright allows owners of the copyrighted work(s) to
govern proposed use and ensures proper attribution.
Licenses for copyrighted data can be tailored to accom-
modate conditional reuse; alternatively a standard Crea-
tive Commons Attribution (CC BY) license can be
applied.33 Researchers should be aware of the ability touse a contract to enable data reuse through licensing,
while protecting intellectual property rights (eg, granting
permission for access while restricting downstream
reuse).34 Clinical Study Data Request provides a contract
template that can be adopted for executing a data use
agreement.35
Clearly noting data terms of use, not overstating
disclosure risks, and carefully reviewing sponsorship
agreements help limit unnecessary time and confusion for
researchers seeking to productively share or reuse data.
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Therapy
Besides Findability and Accessibility which was the
focus of the previous sections, another important aspect of
FAIR is interoperability, which refers to the ability of data
sets to be combined with other data. A fundamental
component of interoperability is adherence to standard
nomenclature and formats. As the leading organization in
radiation oncology, ASTRO encourages good steward-
ship of radiation therapyespecific data elements. The
radiation therapy community has begun to publish stan-
dard nomenclatures, such as AAPM TG 263, that
recommend naming conventions for the regions of inter-
est used for treatment planning.36 When data are shared,
where and when possible, the data should adhere to
community-recognized standards and formats (Table 3).
When it is not possible to align with standard nomen-
clatures, it is critical to be clear of the meaning of eachTable 3 Standard nomenclature and formats recognized in radiati
Resource D
NCI Thesaurus (NCIt) “
American Association of Physicists in Medicine Task Group
263: Standardizing Nomenclatures in Radiation Oncology
“
DICOM-RT and Its Utilization in Radiation Therapy “
Radiation Oncology Ontology (ROO) Tdata element provided in the shared data. Additional ef-
forts in ASTRO are underway on defining the minimum
data elements that should be available on all radiation
therapy treatments.40 These initiatives are expected to
improve the information on radiation treatments admin-
istered in clinical trials and in other studies, thereby
allowing cross-study comparisons of radiation treatments.
Conclusions
Although ASTRO journals do not require data sharing,
ASTRO is committed to research integrity and trans-
parency. The sharing of research data is one way to
embrace these important principles. The best practices
described in this article reflect increasingly common as-
pirations of publishers, funders, and research institutions,
which aim to foster better data stewardship and facilitate
scientific discovery by making data FAIR. In conjunction
with FAIR data principles, the NIH released its program,on therapy
escription
NCI Thesaurus (NCIt) is NCI's reference terminology and
ontology. NCIt provides responsive, science-based
terminology concepts used in NCI semantic infrastructure
and information systems. It covers terminology for clinical
care, translational, and basic research, and public information
and administrative activities.”37
Nomenclature guidelines and values in radiation oncology for
use in clinical trials, data-pooling initiatives, population-
based studies, and routine clinical care by standardizing: (1)
structure names across image processing and treatment
planning system platforms; (2) nomenclature for dosimetric
data (eg, dose-volume histogram-based metrics); (3)
templates for clinical trial groups and users of an initial subset
of software platforms to facilitate adoption of the standards;
(4) formalism for nomenclature schema, which can
accommodate the addition of other structures defined in the
future.”36
In addition to the protocol used in the DICOM standard, 7
DICOM-RT objectsdnamely, RT Image, RT Structure Set,
RT Plan, RT Dose, RT Beams Treatment Record, RT Brachy
Treatment Record, and RT Treatment Summary
Recorddhave been created, each with a well-defined data
model. The data models set the standard for integration of
radiation therapy information for an electronic patient record
and would facilitate the interoperability of different radiation
therapy systems, thus making possible the sharing of
information from different systems.”38
he Radiation Oncology Ontology (ROO) aims to cover the
radiation oncology domain with a strong focus on reusing
existing ontologies. ROO models terms including: uniform
and nonuniform margins; ROI target volumes and organs-at-
risk; dose-volume histogram parameters (Dx, Vx, MLD,
etc.); and online or off-line setup protocols.39
Advances in Radiation Oncology: OctobereDecember 2019 ASTRO journals’ data sharing policy and best practices 557New Models of Data Stewardship, in hopes of acceler-
ating biomedical research.41 ASTRO members and affil-
iates are encouraged to also familiarize themselves with
the NIH strategy for data science which provides a
roadmap for NIH-funded biomedical data.42
Authors submitting to ASTRO’s journals can help
enable FAIR data by doing the following: (1) adhere to
anonymization, nomenclature, and format standards; (2)
deposit research data into a trusted FAIR repository; (3)
cite and link to the data in the article, following the Joint
Declaration of Data Citation Principles;6 (4) include a
data availability statement describing how the data
underlying published findings can be accessed, if data are
unavailable, and or if restrictions exist.
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